Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Abilify

PreclinicalSmall molecule

KKorea Otsuka Pharmaceutical Co., Ltd.

1

Indications

8

Total Trials

0

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

BOSUnknown status

BOSPreclinical

Unknown status

Clinical

Trials by Indication[1]

Bipolar Disorder2 trials

Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness

Completed·KKorea Otsuka Pharmaceutical Co., Ltd.·Phase 4·NCT00545675·146 enrolled

Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness

Completed·KKorea Otsuka Pharmaceutical Co., Ltd.·Phase 4·NCT00545142·280 enrolled

Schizophrenia2 trials

Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 4·NCT00299702·355 enrolled

The New Strategy for Pharmacological Treatment in People With Schizophrenia

Unknown status·IInje University·Phase 4·NCT00352339·90 enrolled

Aripiprazole1 trial

Bioequivalence Study of Aripiprazole From Apipe 10 mg Orally Disintegrating Tablets (Man. by: P&C Labs (Pellets & CR Products), Egypt) Versus Abilify 10 mg Orodispersible Tablets (Otsuka Pharmaceutical Netherlands B.V., Netherlands)

Completed·GGenuine Research Center, Egypt·Phase 1·NCT05804721·29 enrolled

Adult Subject1 trial

Bioequivalence Study of Aripiprazole in Healthy Adult Subjects Under Fasting Condition

Completed·FFuture University in Egypt·Phase 1·NCT05532254·31 enrolled

Hyperprolactinemia1 trial

Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia

Unknown status·GGenovate Biotechnology Co., Ltd.,·Phase 4·NCT00541554

1 more indication

BOS1 trial

Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition

Unknown status·CChengdu Kanghong Pharmaceutical Group Co., Ltd.·N/A·NCT03232710·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Abilify. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Abilify compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Abilify. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Korea Otsuka Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKorea Otsuka Pharmaceutical Co., Ltd.

Related News